NEW YORK – Thermo Fisher Scientific announced yesterday a three-year, C$6 million (US$4.5 million) collaboration with Genome Canada and the Ontario Institute for Cancer Research (OICR) to develop targeted next-generation sequencing-based assays and analysis software.
Under the terms of the agreement, the partners will develop three assays, one for rapid diagnosis of pancreatic cancer, and two for targeted treatments — in prostate and breast cancer.